Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 2OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

telitacicept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Muscle Weakness × Clear all
NCT05451212 2025-11-10

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

Cabaletta Bio

Phase 1 Completed
7 enrolled

Autoimmune Diseases, Immune System Diseases, Musculoskeletal Diseases, Myasthenia Gravis, Neuromuscular Diseases, Muscle Weakness

NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon âš¡